Finally, high-dose radiation in combination with a TLR9 agonist in pre-clinical tumor models enhanced anti-tumor immune responses via increasing activated CD4+ and CD8+ T cells within the tumor microenvironment [34]. This evidence concerns the gene CD4 and neoplasm.